GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom
GSK shares slipped 0.6% to 1,879.5p in London by 10:50 GMT as investors awaited detailed data from its phase III hepatitis B drug trial. Analysts pressed for cure rate and durability figures after GSK withheld specifics. A royalty dispute over cancer drug Jemperli is pending in U.S. court, with a trial set for July 2026. Investors are watching for updates at the Jan. 13 J.P. Morgan conference and Feb. 4 results.